SRRK — Scholar Rock Holding Corporation
$43.20
+$0.05 (+0.10%)
Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on improving the lives of children and adults with spinal muscular atrophy (SMA) and other rare, severe, and debilitating neuromuscular diseases. The company's novel understanding of the molecular mechanisms of growth factor activation within the transforming growth factor beta (TGFß) superfamily has enabled the development of a proprietary platform.
Market Cap
$5.27B
Forward P/E
-17.6x
52-Week Range
N/A
SRRK Price History
Revenue vs. Net Income
$0
Revenue · FY2025
Annual. Net margin is shown under each year.
Free Cash Flow
-$301M
FCF · FY2025
Annual. FCF margin is shown under each year.
Return on Capital Employed (ROCE)
-106.4%
ROCE · FY2025
Annual. Green above 0%, red below. Dashed line marks the 15% compounder threshold.
Total Assets vs. Total Liabilities
2.5x
Assets ÷ liabilities · FY2025
Annual. What the company owns against what it owes. Assets ÷ liabilities is shown under each year.
CapEx as % of Revenue
3.2%
CapEx · FY2022
Annual. Green at or under the 5% maximum target, red above it.
Shares Outstanding
+14.9%
Dilution · FY2025
Annual diluted shares. Under each year: the change on the previous year (green = buyback, amber = dilution).
